TaBriX founder Dr Lydia Tabernero recently spoke at the Bionow BioInfect 2026 conference, held at Alderley Park, one of the UK’s leading life sciences campuses.
BioInfect is Bionow’s flagship conference focused on antimicrobial resistance (AMR) and infection innovation, bringing together experts from research, clinical practice, biotech, pharma and policy to address one of the most pressing global healthcare challenges. The 2026 event centred on collaboration, innovation and action, with key discussions covering pipeline development, diagnostics, vaccines, funding and strategies to tackle resistance more effectively.
Dr Tabernero’s involvement in the event reinforces TaBriX’s strong position within the infectious disease and antimicrobial innovation space. Her insights contributed to important conversations around scientific progress and the collaborative approaches needed to address the growing AMR challenge.
Participation in BioInfect further reflects TaBriX’s mission to support breakthrough science that can make a meaningful difference to global health outcomes.
